单位：[1]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, P. R. China临床科室国家中心消化分中心消化内科首都医科大学附属北京友谊医院[2]General Department, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.[3]Chemotherapy Department, Shandong Tumor Hospital and Institute, Jinan, P. R. China.
Purpose: To investigate the efficacy and safety of gemcitabine plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC). Methods: Eligible patients received gemcitabine 1,000 mg/m(2) on days 1 and 8, and capecitabine 1,000 mg/m(2) twice daily on days 1-14. The treatment was repeated every 3 weeks for a maximum of 6 cycles. The primary endpoint was objective response rate (ORR). The secondary endpoint included progression-free survival (PFS), overall survival (OS), and toxicity. Results: Forty-eight patients with a median age of 72 years (range, 65-83) were included. The ORR according to Response Evaluation Criteria in Solid Tumors (RECIST) was 29.2% (95% confidence interval ([CI], 16.3% to 42.1%). After a median follow-up of 17.4 months, median PFS and OS were 6.4 months (95% CI, 5.2-7.6) and 18.0 months (95% CI, 14.8-21.2), respectively. Grade 3 to 4 adverse events included neutropenia (20.8%), asthenia (8.3%), hand foot syndrome (6.3%), abnormal liver function (6.3%), diarrhea (6.3%), constipation (2.1%) and thrombocytopenia (2.1%). Neutropenic fever occurred in one patient. Conclusions: Gemcitabine plus capecitabine are active and safe in elderly patients with anthracycline- and taxane-pre-treated MBC.
基金：
Scientific Research Foundation, Beijing Friendship Hospital, Capital Medical University, China [yyqdkt2019-77]
第一作者单位：[1]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, P. R. China
通讯作者：
通讯机构：[1]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, P. R. China[*1]No.95, Yong-an Rd, Xicheng District, Beijing 100050, China
推荐引用方式(GB/T 7714)：
Dong Ningning,Wu Yongdong,Song Chenxin,et al.Gemcitabine plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer[J].JOURNAL of BUON.2020,25(3):1348-1353.
APA：
Dong, Ningning,Wu, Yongdong,Song, Chenxin,Wang, Mingyu,Jiao, Yue&Zhang, Shutian.(2020).Gemcitabine plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.JOURNAL of BUON,25,(3)
MLA：
Dong, Ningning,et al."Gemcitabine plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer".JOURNAL of BUON 25..3(2020):1348-1353
